From: A pooled analysis of mesenchymal stem cell-based therapy for liver disease
Study | Country | Study design | Patient populations | Sample size (MSC/control) | Average age (MSC/control) | Male (%) | Cell type | Delivery route | Times of injection | Dosage of MSCs/ml | Number of MSCs | Maximum follow-up (months) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Y. Du, 2011 [37] | China | nRCT | Decompensated liver cirrhosis | 25/25 | 53 | 82.0% | UC-MSCs | Artery | Multiple | 1 | (0.1–1.0) × 108 cells | 2 |
L. Peng, 2011 [38] | China | nRCT | Liver failure | 6/15 | 42.19/42.22 | 94.3% | B-MSCs | Artery | Single | 10 | 1 × 107 cells | 12 |
Amer ME, 2011 [27] | Egypt | RCT | End-stage liver failure | 20/20 | 50.5/50.0 | 82.5% | B-MSCs | Intrasplenic vs intrahepatic | Single | 5 | NR | 6 |
China | RCT | Decompensated liver cirrhosis | 38/16 | 47/48 | 90.7% | UC-MSCs | Vein | Multiple | 60 | (0.5–1.0) × 106/kg | 12 | |
Z. Zhang, 2012 [28] | China | RCT | Decompensated liver cirrhosis | 30/15 | 48/47 | 88.9% | UC-MSCs | Vein | Multiple | NR | 0.5 × 106/kg | 12 |
El-Ansary M, 2012 [39] | Egypt | nRCT | Advanced liver cirrhosis | 15/10 | 48/51.6 | 76.0% | B-MSCs | Vein | Single | NR | 1 × 106/kg | 6 |
J. Yu, 2012 [40] | China | nRCT | End-stage liver failure | 13/22 | 43.46/47.45 | 82.9% | B-MSCs | Vein | Single | 100 | 5 × 106 cells | 1 |
Y. Zhang, 2012 [29] | China | RCT | Decompensated liver cirrhosis | 12/18 | 48.63/49.86 | 70.0% | UC-MSCs | Artery | Single | 10 | ≥ 2 × 107 cells | 3 |
S. Ouyang, 2013 [41] | China | nRCT | Decompensated liver cirrhosis | 33/34 | 53.1/55.2 | 83.6% | B-MSCs | Artery | Single | 5 | (3–5) × 106 cells | 6 |
M. Zhu, 2013[42] | China | nRCT | Decompensated liver cirrhosis | 22/20 | 48.5/49.2 | 81.0% | UC-MSCs | Vein | Multiple | 100 | 1 × 108 cells | 2 |
B. Liu, 2013[43] | China | nRCT | Acute-on-chronic liver failure | 16/19 | 38.7 | 80.0% | UC-MSCs | Vein vs artery | Single | NR | > 5 × 107 cells | 3 |
Q. Wang, 2013 [30] | China | RCT | Chronic liver failure | 9/9 | 50.71 (median) | 85.7% | UC-MSCs | Vein | Multiple | NR | (1.2–6.2) × 107/ml | 4 |
L. Xu, 2014 [31] | China | RCT | Liver cirrhosis | 20/19 | 44/45 | 61.5% | B-MSCs | Artery | Single | 20 | 4 × 107 cells | 6 |
Mohamadnejad M, 2013 [11] | Iran | RCT | Decompensated liver cirrhosis | 14/11 | 43.1/34.6 | 52.0% | B-MSCs | Vein | Single | 100 | 1.95 × 108 cells | 12 |
H. Salama, 2014 [32] | Egypt | RCT | End-stage liver disease | 20/20 | 50.27/50.9 | 82.5% | B-MSCs | Vein | Single | 100 | 1 × 106/kg | 6 |
L. Zhuang, 2014 [44] | China | nRCT | Liver cirrhosis | 29/35 | 55/56 | 78.1% | UC-MSCs | Portal vein | Single | NR | 0.5 × 108 cells | 6 |
H. He, 2015 [45] | China | nRCT | Acute-on-chronic liver failure | 46/54 | 43.8/44.5 | 89.0% | UC-MSCs | Vein | Multiple | 100 | 1 × 105/kg | 3 |
H. Luo, 2015 [46] | China | nRCT | Decompensated liver cirrhosis | 50/46 | 43/44 | 88.5% | UC-MSCs | Vein | Multiple | 100 | NR | 3 |
L. Tong, 2015 [47] | China | nRCT | Decompensated liver cirrhosis | 20/20 | 56.4/56 | 55.0% | UC-MSCs | Vein | Multiple | 100 | (2–4) × 109 cells | 6 |
Y. Li, 2015 [33] | China | RCT | Acute-on-chronic liver failure | 31/27 | 41.6/43.1 | 89.7% | UC-MSCs | Vein | Multiple | 60 | (0.5–1.0) × 106/kg | 12 |
D. Zhang, 2016 [36] | China | RCT | Hepatic fibrosis | 30/30 | 30.98/32.1 | 55.0% | B-MSCs | Vein | Multiple | 2 | 6 × l06 cells | 3 |
K.T. Suk, 2017 [34] | South Korea | RCT | Liver cirrhosis | 37/18 | 53.7/53.7 | 89.1% | B-MSCs | Artery | Single vs multiple | 10 | 5 × 107 cells | 12 |
B.-L. Lin, 2017 [35] | China | RCT | Acute-on-chronic liver failure | 56/54 | 40/42.8 | 94.5% | B-MSCs | Vein | Multiple | 10 | 1 × 103 to 1 × 105/kg | 6 |
J. Shen, 2015 [26]a | China | nRCT | Decompensated liver cirrhosis | 28/28 | 42.4 | 94.6% | B-MSCs | Artery | Single | NR | (1.7 ± 0.4) × 107/ml | 36 |
Kantarcioʇlu M, 2015 [62] | Turkey | Uncontrolled | Liver cirrhosis | 12 | 39 | 58.3% | B-MSCs | Vein | Single | NR | 1 × 106/kg | 12 |
M. El-Ansary, 2010 [48] | Egypt | Uncontrolled | Chronic liver failure | 12 | 49.67 | 75.0% | B-MSCs | Intrasplenic vs vein | Single | 5 | 1 × 106 cells | 6 |
J. Chen, 2015 [49] | China | Uncontrolled | Decompensated liver cirrhosis | 27 | 45.22 | 63.0% | UC-MSCs | Vein | Multiple | 20 | ≥ 2 × 107 cells | 3 |
Z. Wang, 2013 [50] | China | Uncontrolled | Liver cirrhosis | 10 | 53.7 | 90.0% | B-MSCs | Artery | Single | NR | 1 × 106/kg | 3 |
L. Wang, 2013 [51] | China | Uncontrolled | Liver cirrhosis | 10 | 49 | 10.0% | B-MSCs | Vein | Single | 20 | (0.5–1.0) × 106/kg | 12 |
Li. Wang, 2013 [52] | China | Uncontrolled | Decompensated liver cirrhosis | 23 | 57.3 | 69.6% | UC-MSCs | Both vein and artery | Multiple | 50 | NR | 12 |
H. Zhang, 2013 [53] | China | Uncontrolled | Decompensated liver cirrhosis | 25 | 18–72 (range) | 84.0% | B-MSCs | Artery | Single | 3-5 | (3–5) × 107 cells | 3 |
J. Li, 2012 [54] | China | Uncontrolled | Liver cirrhosis | 87 | 46.9 | 65.5% | B-MSCs | Artery | Single | NR | 1 × 106 /kg | 2 |
J. Wang, 2012 [55] | China | Uncontrolled | Decompensated liver cirrhosis | 21 | 46 | 90.5% | UC-MSCs | Vein | Single | 30 | (0.6–1.5) × 109 cells | 3 |
J. Guo, 2012 [56] | China | Uncontrolled | Decompensated liver cirrhosis | 15 | 32 | 66.7% | UC-MSCs | Both vein and artery | Multiple | 20 | (2–6) × 107 cells | 3 |
B. Zhou, 2011 [57] | China | Uncontrolled | Decompensated liver cirrhosis | 60 | 57.97 | 58.3% | UC-MSCs | Artery | Single | 40 | 2 × 107 cells | 3 |
H. Yu, 2011 [58] | China | Uncontrolled | Decompensated liver cirrhosis | 10 | 6.78 | 100.0% | UC-MSCs | Artery | Single | NR | 2 × 107 cells | 6 |
D. Niu, 2011 [59] | China | Uncontrolled | Autoimmune liver disease | 7 | 53–68 (range) | 28.6% | UC-MSCs | Vein | Multiple | NR | 8 × 107 cells | 12 |
H. Chen, 2011 [60] | China | Uncontrolled | Chronic liver failure | 20 | 45.2 | 70.0% | B-MSCs | Artery | Single | 50 | ≥ 1 × 109 cells | 3 |
X. Jin, 2012 [61] | China | Uncontrolled | Decompensated liver cirrhosis | 24 | 45.6 | 83.3% | UC-MSCs | Vein | Single | 10 | 2 × 107 cells | 3 |